SCHEMBL25698686

SCHEMBL25698686

COC(C)(C)C(=O)Nc1cc(B2OC(C)(C)C(C)(C)O2)ccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K1 Q92918 1/20 0.45
DGAT1 O75907 1/20 0.42
HIF1A Q16665 5/20 0.42
BUB1 O43683 1/20 0.38
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
AAK1 Q2M2I8 2/20 0.36
GSK3A P49840 1/20 0.35
GSK3B P49841 1/20 0.35
PDGFRB P09619 1/20 0.35
KDR P35968 1/20 0.35
ABL1 P00519 1/20 0.35
ALPL P05186 1/20 0.34
F2 P00734 1/20 0.34
F11 P03951 1/20 0.34
PRSS1 P07477 1/20 0.34
PRSS2 P07478 1/20 0.34
PRSS3 P35030 1/20 0.34
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25698688 0.88 CYP1A2 (0.43) DGAT1HIF1APRMT5WDR77AAK1
SCHEMBL16923787 0.84 JAK2 (0.43) DGAT1HIF1APRMT5WDR77AAK1
SCHEMBL25698689 0.82 MAP4K1 (0.46) MAP4K1DGAT1HIF1ABUB1PRMT5
SCHEMBL29393739 0.82 PRMT5 (0.48) DGAT1HIF1APRMT5WDR77AAK1
SCHEMBL9979047 0.82 PRMT5 (0.48) DGAT1HIF1APRMT5WDR77AAK1
SCHEMBL477041 0.81 HIF1A (0.42) DGAT1HIF1AGSK3AGSK3BPDGFRB
SCHEMBL29429879 0.81 L3MBTL1 (0.44) HIF1AGSK3AGSK3BPDGFRBKDR
SCHEMBL626853 0.81 L3MBTL1 (0.44) HIF1AGSK3AGSK3BPDGFRBKDR
SCHEMBL1555262 0.80 HIF1A (0.47) DGAT1HIF1AGSK3AGSK3BABL1
SCHEMBL28749629 0.78 AAK1 (0.40) DGAT1HIF1APRMT5WDR77AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 US disclosed
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-08-17 US disclosed
WO-2023108108-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257352-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF BRAF, RAF1, ARAF MAP4K1 30/4885DGAT1 2091/4885HIF1A 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.